Inspired by the acquisition of Cord Blood Registry by AMAG Pharmaceuticals for $700M in June of 2015, this post considers five cord blood investors that are impacting the global marketplace. It includes traditional investments, acquisitions, and contributions from wealthy founders. If you are operating within the cord blood industry, you need to know these market investors. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Gamida Cell Transplants First Patient in Phase 1/2 Study of CordIn™ for Severe Aplastic Anemia and Hypoplastic MDS
This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI)
Jerusalem, Israel, August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. CordIn™ is produced by Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. [Read more…]
Cord Blood Transplantation with Dr. Milano of Fred Hutchinson
I had the honor of interviewing Dr. Filippo Milano, Associate Director of Cord Blood Transplantation at the Fred Hutchinson Cancer Research Centre about cord blood transplantation. In this interview, Dr. Milano speaks about trends in cord blood transplantation (CBT) that are affecting the global cord blood industry. [Read more…]
Donor Egg Bank to Provide Free Cord Blood Processing through FamilyCord
World’s Largest Frozen Egg Bank offers a Lifetime of Security
Rockville, MD, Aug. 1, 2017— Donor Egg Bank, a California Cryobank company, continues to set the standard for the frozen donor egg industry by offering a truly once in lifetime opportunity to their intended parents – free processing for their future babies’ cord blood stem cells through sister company FamilyCord – a $1,500 savings.
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments
Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join the Company as its new Chief Medical Officer (CMO) based in the U.S. [Read more…]
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 62
- Next Page »